Research programme: respiratory syncytial virus vaccines - BlueWillow Biologics
Alternative Names: Nanoemulsion adjuvanted intramuscular RSV vaccine - BlueWillow Biologics; Nanoemulsion adjuvanted intranasal RSV vaccine - BlueWillow Biologics; NE-RSV vaccineLatest Information Update: 28 Mar 2022
At a glance
- Originator NanoBio Corporation
- Developer BlueWillow Biologics
- Class Respiratory syncytial virus vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Respiratory syncytial virus infections
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for preclinical development in Respiratory-syncytial-virus-infections(Prevention) in USA (Intranasal)
- 09 Mar 2020 Respiratory-syncytial-virus-infections - BlueWillow Biologics is still in preclinical development in Respiratory-syncytial-virus-infections(Prevention) in USA (Intranasal) (BlueWillow Biologics pipeline March 2020)
- 09 Mar 2020 No development reported - Preclinical for Respiratory syncytial virus infections (Prevention) in USA (IM) (BlueWillow Biologics pipeline March 2020)